This concerned six appraisals for PD-(L)1 inhibitors (TA428, TA520, TA600, TA683, TA705 and TA724), and appraisals of treatments targeting ALK (TA628 and TA670), EGFR (TA595), ROS1 (TA529), and indications adenocarcinoma (TA347) and NSCLC (TA403). Here, ALK is linked to non-small cell lung carcinoma.